Results 41 to 50 of about 268,746 (338)

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors [PDF]

, 2019
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium ...
Au, L, Chauhan, D, Edmonds, K, Gore, M, Hughes, P, Husson, O, Lai, Z, Larkin, J, Lingard, K, Ludlow, A, Lynch, J, Mann, J, Mclean, E, O'Reilly, A, Pattison, N, Teh, JJ, Turajlic, S, Wiseman, T   +17 more
core   +3 more sources

Research Progress of Immune Checkpoint Inhibitors in Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2020
Tumor immunity is a new line of research for the treatment of patients with solid tumors, and negative regulators of the immune system called immune checkpoints play a key role in limiting antitumor immunologic responses.
ZHUANG Yuwen, SHEN Junyi, LIU Shenlin, CAI Hui   +3 more
doaj   +1 more source

Research Progress of Immune Checkpoint Therapy on Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2021
At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj   +1 more source

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

Безопасность и риск фармакотерапии, 2020
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), has improved the prognosis of ...
E. V. Shubnikova, T. M. Bukatina, N. Yu. Velts, D. A. Kaperko, G. V. Kutekhova   +4 more
doaj   +1 more source

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Frontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger   +7 more
doaj   +1 more source

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma, Florento, Elena, Gatalica, Zoran, Palazzo, Juan, Sanati, Souzan, Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne   +7 more
core   +2 more sources

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Ophthalmology and Therapy
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj   +1 more source

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? [PDF]

, 2019
Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent.
Badalamenti G., Bazan V., Fanale D., Fulfaro F., Incorvaia L., Iovanna J. L., Olive D., Rinaldi G., Russo A., Swayden M., Terruso L., Vincenzi B.   +11 more
core   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura, Kentaro Ueno, Takuro Nishikawa, Yoshihiro Takahashi, Koji Nakae, Yasuhiro Okamoto   +5 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source